Rhapontin

Overview

Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Depression | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-N0671
• CAS No.: 155-58-8
• Molecular Formula: C21H24O9
• Molecular Weight: 420.41
• Purity: 99.73%
• Storage: 4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
• Solubility: ≥ 2.08 mg/mL (4.95 mM); Clear solution
• Availability: In-stock

Source

Original product source